Redenlab supporting PTC Theraputics in Global Phase 3 Clinical Trial

Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich #Ataxia.

The Phase 3 MOVE-FA trial is an 18-month parallel arm, placebo-controlled study evaluating vatiquinone versus placebo in approximately 110 children and young adults with FA. The primary endpoint is the change from baseline in the modified Friedreich ataxia rating scale (mFARS), with key secondary endpoints assessing ambulation and activities of daily living (incl #speech). This endpoint strategy was developed in consultation with both the FDA and European Medicines Agency. The study will include sites in the U.S., E.U., Australia and Latin America.

Click here for more details.

Related Post

  • Posted on 17 June, 2025
    A new study published in the European Journal of Human Genetics provides the first systematic analysis of speech and language...
    • Posted on 15 May, 2025
      MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap for the...
      • Posted on 11 December, 2024
        MEDIA RELEASE Melbourne - December 2024 – Redenlab, a leader in innovative healthcare solutions, has partnered with the Queensland Institute of Medical...